NCT00116909

A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 85 (planned)
• Sponsor: OSI Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy

Conditions

• Locally Recurrent or Metastatic Cancer of the Head and Neck
• Must Have Failed First-Line Therapy

Interventions

Type	Name	Description
DRUG	OSI 7904L

Timeline

• Start date: 2004-08-01
• Completion: 2005-08-01
• First posted: 2005-07-01
• Last updated: 2007-03-14

Locations

4 sites across 1 country: United States